Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 310
Selected: 0
NCT IDTitle
NCT01192399Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT02797821Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
NCT01849562Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
NCT05346354Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT00838513Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05047523Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
NCT06015750Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
NCT03075904A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
NCT01454986Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
NCT00485576Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
NCT00984113Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
NCT04155424A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
NCT00380159Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
NCT04581785Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia
NCT01895127Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
NCT00744042Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
NCT04551586A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
NCT07337395Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
NCT00648739Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
NCT06291376Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT05428696Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants
NCT02193867Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
NCT02245412A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
NCT06449001Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
NCT03723512Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
NCT03329365Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
NCT02796885Characterisation of Adult-Onset Hypophosphatasia
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT05368038ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT03218241Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT03310021A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT04725812Complement Regulation to Undo Systemic Harm in Preeclampsia
NCT03661528Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
NCT00312039Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
NCT07413679Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
NCT04970004Study in Adult and Pediatric Patients With HSCT-TMA
NCT02293408Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
NCT01919346Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
NCT02324049Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT04660890A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
NCT01307098Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency
NCT02345421A Study to Identify and Characterize LAL-D Patients in High-risk Populations
NCT04451434Study of Danicopan in Participants of Japanese Descent
NCT02946463ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04952545Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
NCT00999336A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment
NCT05578846Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics
NCT04189315Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease
NCT06764160Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
NCT07308574Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS